These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 22335516

  • 1. Emerging targets for the pharmacological treatment of depression: focus on melatonergic system.
    Catena-Dell'Osso M, Marazziti D, Rotella F, Bellantuono C.
    Curr Med Chem; 2012; 19(3):428-37. PubMed ID: 22335516
    [Abstract] [Full Text] [Related]

  • 2. Melatonergic drugs in clinical practice.
    Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP.
    Arzneimittelforschung; 2008; 58(1):1-10. PubMed ID: 18368944
    [Abstract] [Full Text] [Related]

  • 3. Agomelatine in depressive disorders: its novel mechanisms of action.
    Srinivasan V, Zakaria R, Othman Z, Lauterbach EC, Acuña-Castroviejo D.
    J Neuropsychiatry Clin Neurosci; 2012; 24(3):290-308. PubMed ID: 23037643
    [Abstract] [Full Text] [Related]

  • 4. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.
    de Bodinat C, Guardiola-Lemaitre B, Mocaër E, Renard P, Muñoz C, Millan MJ.
    Nat Rev Drug Discov; 2010 Aug; 9(8):628-42. PubMed ID: 20577266
    [Abstract] [Full Text] [Related]

  • 5. Circadian rhythms, melatonin and depression.
    Quera Salva MA, Hartley S, Barbot F, Alvarez JC, Lofaso F, Guilleminault C.
    Curr Pharm Des; 2011 Aug; 17(15):1459-70. PubMed ID: 21476953
    [Abstract] [Full Text] [Related]

  • 6. Agomelatine: innovative pharmacological approach in depression.
    Popoli M.
    CNS Drugs; 2009 Aug; 23 Suppl 2():27-34. PubMed ID: 19708723
    [Abstract] [Full Text] [Related]

  • 7. The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives.
    Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Poeggeler B, Hardeland R, Cardinali DP.
    World J Biol Psychiatry; 2009 Aug; 10(4 Pt 2):342-54. PubMed ID: 18609422
    [Abstract] [Full Text] [Related]

  • 8. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
    Kasper S, Hamon M.
    World J Biol Psychiatry; 2009 Aug; 10(2):117-26. PubMed ID: 19255935
    [Abstract] [Full Text] [Related]

  • 9. Pathophysiology of depression: role of sleep and the melatonergic system.
    Srinivasan V, Pandi-Perumal SR, Trakht I, Spence DW, Hardeland R, Poeggeler B, Cardinali DP.
    Psychiatry Res; 2009 Feb 28; 165(3):201-14. PubMed ID: 19181389
    [Abstract] [Full Text] [Related]

  • 10. [Lights off? Neurobiological and pharmacological aspects of the melatonergic-serotonergic synergism].
    Sumegi A, Somoskovi C.
    Neuropsychopharmacol Hung; 2010 Dec 28; 12(4):469-75. PubMed ID: 21220792
    [Abstract] [Full Text] [Related]

  • 11. Melatonin and melatonergic drugs on sleep: possible mechanisms of action.
    Srinivasan V, Pandi-Perumal SR, Trahkt I, Spence DW, Poeggeler B, Hardeland R, Cardinali DP.
    Int J Neurosci; 2009 Dec 28; 119(6):821-46. PubMed ID: 19326288
    [Abstract] [Full Text] [Related]

  • 12. Melatonergic Receptors (Mt1/Mt2) as a Potential Additional Target of Novel Drugs for Depression.
    Boiko DI, Shkodina AD, Hasan MM, Bardhan M, Kazmi SK, Chopra H, Bhutra P, Baig AA, Skrypnikov AM.
    Neurochem Res; 2022 Oct 28; 47(10):2909-2924. PubMed ID: 35689787
    [Abstract] [Full Text] [Related]

  • 13. Synergistic mechanisms involved in the antidepressant effects of agomelatine.
    Tardito D, Molteni R, Popoli M, Racagni G.
    Eur Neuropsychopharmacol; 2012 Oct 28; 22 Suppl 3():S482-6. PubMed ID: 22867907
    [Abstract] [Full Text] [Related]

  • 14. Melatonin and synthetic melatonergic agonists: actions and metabolism in the central nervous system.
    Hardeland R, Poeggeler B.
    Cent Nerv Syst Agents Med Chem; 2012 Sep 28; 12(3):189-216. PubMed ID: 22640220
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic potential of agomelatine in epilepsy and epileptic complications.
    Vimala PV, Bhutada PS, Patel FR.
    Med Hypotheses; 2014 Jan 28; 82(1):105-10. PubMed ID: 24314750
    [Abstract] [Full Text] [Related]

  • 16. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
    De Berardis D, Di Iorio G, Acciavatti T, Conti C, Serroni N, Olivieri L, Cavuto M, Martinotti G, Janiri L, Moschetta FS, Conti P, Di Giannantonio M.
    CNS Neurol Disord Drug Targets; 2011 Feb 28; 10(1):119-32. PubMed ID: 20874703
    [Abstract] [Full Text] [Related]

  • 17. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.
    Guardiola-Lemaitre B, De Bodinat C, Delagrange P, Millan MJ, Munoz C, Mocaër E.
    Br J Pharmacol; 2014 Aug 28; 171(15):3604-19. PubMed ID: 24724693
    [Abstract] [Full Text] [Related]

  • 18. Agomelatine: efficacy at each phase of antidepressant treatment.
    Kennedy SH.
    CNS Drugs; 2009 Aug 28; 23 Suppl 2():41-7. PubMed ID: 19708725
    [Abstract] [Full Text] [Related]

  • 19. The interaction between the internal clock and antidepressant efficacy.
    Racagni G, Riva MA, Popoli M.
    Int Clin Psychopharmacol; 2007 Oct 28; 22 Suppl 2():S9-S14. PubMed ID: 17917564
    [Abstract] [Full Text] [Related]

  • 20. The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice.
    De Berardis D, Marini S, Fornaro M, Srinivasan V, Iasevoli F, Tomasetti C, Valchera A, Perna G, Quera-Salva MA, Martinotti G, di Giannantonio M.
    Int J Mol Sci; 2013 Jun 13; 14(6):12458-83. PubMed ID: 23765220
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.